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Background: The currently recom-
mended frequency for prostate-specific
antigen (PSA) screening tests for pros-
tate cancer is 1 year, but the optimal
screening interval is not known. Our
goal was to determine if a longer inter-
val would compromise the detection of
curable prostate cancer. Methods: A co-
hort of 4491 men aged 55–75 years, all
participants in the Rotterdam section
of the European Randomized Study of
(population-based) Screening for Pros-
tate Cancer, were invited to participate
in an initial PSA screening. Men who
received that screening were invited for
a second screen 4 years later. Pathology
findings from needle biopsy cores were
compared for men in both rounds. Sta-
tistical tests were two-sided. Results:
A total of 4133 men were screened in
the first round (the prevalence screen),
and 2385 were screened in the second
round. The median amount of cancer in
needle biopsy sets was 7.0 mm (95%
confidence interval [CI] = 5.4 mm to
8.6 mm) in the first round and 4.1 mm
(95% CI = 2.6 mm to 5.6 mm) in the
second round (P = .001). Thirty-six per-
cent of the adenocarcinomas detected
in the first round but only 16% of those
detected in the second round had a
Gleason score of 7 or higher (mean dif-
ference = 20% [95% CI = 10% to
30%]; P<.001). Whereas 25% of the
adenocarcinomas detected in the first
round had adverse prognostic features,
only 6% of those detected in the second
round did (mean difference = 19%
[95% CI = 11% to 26%]; P<.001).
Baseline PSA values were predictive
for the amount of tumor in biopsies in
men with cancer in the first round but
not for that in the second round. Con-
clusion: Most large prostate cancers
with high serum PSA levels were effec-
tively detected in a prevalence screen.
In this population, a screening interval
of 4 years appears to be short enough to
constrain the development of large tu-
mors, although it is inconclusive wheth-
er this will result in a survival benefit.
[J Natl Cancer Inst 2001;93:1153–8]
Prostate cancer is rapidly becoming a
major health problem in Western coun-
tries. Epidemiologic studies show that it is
now the second most commonly diag-
nosed malignancy in men after nonmela-
notic skin cancer. In the United States,
prostate cancer mortality is second only to
mortality caused by lung cancer (1). The
clinical incidence of prostate cancer has
risen substantially during the last decade
since the introduction of serum prostate-
specific antigen (PSA) measurement as a
tool for identifying men at risk for pros-
tate cancer. The introduction and wide-
spread use of this relatively cheap and
simple test have resulted in mass screen-
ing of clinically asymptomatic men, espe-
cially in Western countries. Since 1993,
the American Cancer Society has recom-
mended annual serum PSA tests in
asymptomatic men 50 years of age or
older (2).
A potential and undesirable side effect
caused by increased efforts for early de-
tection of prostate cancer is an increased
chance of detecting carcinomas that, had
they remained undetected, would never
have led to morbidity or mortality. At au-
topsy, the presence of clinically undiag-
nosed tumors in men 50 years of age or
older is estimated to be at least five times
higher than the lifetime risk for tumors
that lead to morbidity or mortality (3,4).
As of yet, the effects of PSA screening on
overall morbidity, mortality, and quality
of life in the screened population are not
known. Several randomized trials on
screening for prostate cancer are under
way to investigate these questions (5).
Variations in the screening protocol, in-
cluding the interval between different
rounds of screening for prostate cancer,
are likely to have a considerable influence
on the costs of prostate cancer screening
and on the morbidity, mortality, and qual-
ity of life of the screened population.
The results of some studies (6–8) indi-
cate that biannual screening would not
compromise the detection of curable pros-
tate cancers in some or possibly all of the
men at risk for the disease and would lead
to a substantial reduction in health-care
costs. These studies, however, are based
not on clinical experience but rather on
models predicting the probability of pros-
tate cancer in the population at risk using
retrospective data.
To determine whether a longer interval
between screening rounds would compro-
mise the detection of curable prostate can-
cer, we studied prostate cancer character-
istics in a cohort of men during two
rounds of population-based screening for
prostate cancer that were performed in the
Rotterdam University Hospital, The Neth-
erlands. The two rounds were separated
by an interval of 4 years. Histopatholog-
ically assessed tumor characteristics of
screen-detected cancer on needle biopsy
specimens were compared between the
two rounds of screening.
SUBJECTS AND METHODS
The European Randomized Study of Screening
for Prostate Cancer (ERSPC) is a multicenter, ran-
domized, population-based trial that investigates the
impact of systematic PSA screening for prostate
cancer on prostate cancer mortality and quality of
life. The study was approved by a government com-
mission supervising the compliance with the Dutch
law on population screening, and written informed
consent was obtained from every participant before
randomization. This report concerns a cohort of
4491 men aged 55–75 years, all of whom had been
randomly assigned to the screening group in the Rot-
terdam section of ERSPC from June 1994 to March
1996. None of the participants had a previous diag-
nosis of prostate cancer. During the study period,
screening was discontinued in all participants who
reached the age of 75 years. Men who did not re-
spond to the invitation for screening were excluded
from further evaluation in this report. Information
on various reasons for not visiting (e.g., because
men died of other causes or moved out of the area)
was obtained from the local government.
Screening Protocols
First round of screening (prevalence and in-
terim screen). The first round of screening (the
prevalence screen) took place from June 1994 to
March 1996. The 4133 men who accepted the invi-
tation to the first screen underwent serum PSA mea-
surement, digital rectal examination (DRE), and
transrectal ultrasound investigation (TRUS). Biop-
sies were recommended for men whose serum PSA
level was 4 ng/mL or greater or whose DRE or
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TRUS result was abnormal. Men who were recom-
mended for biopsy but who either refused a biopsy
or could not undergo a biopsy for medical reasons
(e.g., because they were receiving anticoagulant
therapy or had a comorbid condition) were excluded
from further evaluation. For men with a benign bi-
opsy outcome, an interim round of screening was
conducted after 1 year. A small number of men
(seven) with benign biopsy outcomes in the first
interim round were reinvited for a second interim
round, which took place 1 year later.
Second round of screening. The second round of
screening took place from June 1998 to March 2000.
All 2385 participants in the second round of screen-
ing had been screened 4 years earlier, and 645 (27%)
of them had undergone an interim screen 3 years
earlier after being recommended for biopsy in the
first round. By the time the second round of screen-
ing began, the screening protocol had changed (9).
In brief, because of the low positive predictive value
and sensitivity of DRE and TRUS, biopsies were
now recommended to all participants with a serum
PSA level of 3 ng/mL or higher, regardless of the
outcome of DRE or TRUS. In addition, the 1-year
interval rescreen after a benign biopsy outcome was
omitted.
Biopsy technique. In participants who complied
with the recommendation for biopsy, systematic
sextant biopsies were obtained during longitudinal
ultrasonographic scanning of the prostate. All biop-
sies were performed with 18-gauge biopsy needles
(Bard Inc., Murray Hill, NJ) driven by a pro-mag
spring-loaded biopsy gun (Manan, Northbrook, IL).
The needles were directed cranially at an angle of
approximately 45 degrees from the transversal plane
and outward at approximately 30 degrees from the
sagittal plane. Each biopsy core was inked at its
capsular end, numbered according to its site of ori-
gin, and sent in a separate container to the pathology
department.
Histopathologic Examination
Processing and examination of biopsy cores.
All biopsy cores were processed for routine histo-
pathologic examination, as described previously
(10). In brief, after fixation in a 4% saline-buffered
formalin solution, every core was embedded sepa-
rately in paraffin, sectioned longitudinally into
5-m sections, and stained with hematoxylin–eosin.
At least three histologic sections of different cutting
levels of each biopsy core were examined.
In each case of prostate cancer, the reference pa-
thologist for urologic pathology (T. H. van der
Kwast) recorded the number of positive biopsy cores
in each sextant set. The length (in millimeters) of
cancer involvement was measured in each core and
calculated for the sextant biopsy set as a whole. All
adenocarcinomas were graded according to the
Gleason scoring system (11). In addition, the length
(in millimeters) and the percentage of high-grade
tumor (i.e., Gleason growth pattern 4 or 5) were
calculated for each sextant biopsy set.
Categorization of cancer involvement and
grade in biopsy sets. Both the amount of tumor
present in biopsy sets and the prostate cancer grade
are prognostic features for biochemical relapse after
treatment with curative intent (12). To account for
the fact that both large well-differentiated tumors
and small poorly differentiated tumors could have a
poor prognosis, we constructed an arbitrary catego-
rization model that combines these tumor features
(Table 1). Category A contains biopsy sets with only
a single small focus of well-differentiated adenocar-
cinoma. In addition to small but potentially danger-
ous tumors, this category is also likely to contain
clinically insignificant tumors. Category B includes
biopsy sets with larger amounts of adenocarcinoma,
which sometimes contain high-grade cancer (Glea-
son growth pattern 4 or 5). This category is likely to
contain prostate cancers that pose a threat to their
host if left untreated. Biopsy sets in category C con-
tain either large amounts of adenocarcinoma or car-
cinomas that consist largely of poorly differentiated
tumor (Gleason growth pattern 4 or 5). Men whose
tumors fall into this category would have a consid-
erable risk of therapy failure.
To validate our categorization model for sextant
biopsy sets, the categorization in the model for sex-
tant biopsy sets of 79 men in the first round of
screening who underwent radical prostatectomy was
compared with clinical follow-up data, i.e., bio-
chemical failure during a 4-year follow-up period
(defined as three consecutive postoperative PSA lev-
els >0.1 ng/mL). Table 1 shows that biopsy catego-
ries of the 79 men were associated with the chance
for extraprostatic tumor growth (Pearson chi-
squared test, two-tailed P .01). Biopsy categories
were also associated with the chance for biochemi-
cal progression after surgery, although this associa-
tion was not statistically significant (Pearson chi-
squared test, two-tailed P  .06).
Comparison of Adenocarcinomas
Found in Different Rounds of
Screening and Statistical Analysis
The characteristics (i.e., amount and grade) of the
adenocarcinomas that were detected in the first
round of screening (the prevalence and interim
screens combined) were compared with those of the
adenocarcinomas that were detected in the second
round of screening. To investigate whether charac-
teristics of second-round adenocarcinomas were dif-
ferent in men who had undergone previous biopsies,
we also compared the characteristics of the adeno-
carcinomas of participants with adenocarcinomas
detected in the second round screen who had and
who had not undergone biopsy during the first round
of screening. Statistical analyses of comparisons be-
tween subsets of distributions based on ordinal vari-
ables, such as Gleason score or the arbitrary biopsy
categories, were performed with a two-sided Pear-
son chi-squared test. The null hypothesis (statistical
independence of the tested variables in subsets of
participants) was rejected for P values under .05.
Statistical analyses of comparisons of characteristics
based on continuous variables with a skewed distri-
bution, such as PSA values or the amount of tumor
or high-grade cancer in biopsy sets, were performed
with a two-tailed Mann–Whitney U test. The null
hypothesis (a similar rank distribution of the tested
variable in subsets of participants) was rejected for P
values under .05.
RESULTS
Participation Rates
Of the 4491 men invited for PSA
screening (after randomization) in the
first round, 4133 (92%) accepted (Table
Table 1. Categories for amount and grade of adenocarcinoma on sextant prostate biopsy sets and comparison with progression after
radical prostatectomy in 79 participants
Category
Criteria
Outcome after radical prostatectomy (n  79)
No. of
cases (%)
Extraprostatic tumor growth,
i.e., stage higher than pT2, at
radical prostatectomy (% of cases)*
Biochemical
progression within
4 y after surgery (%)†Tumor extent Grade
A Only one positive biopsy core, with
30% of the core involved
Only Gleason growth
patterns 1–3
22 (28) 3 (14) 1 (5)
B Only one positive biopsy core, with
>30% of the core involved, or
more than one positive biopsy
core, with a total percentage of
cancer involvement of 30%
Gleason score 7 45 (57) 21 (47) 4 (9)
C All others Any 12 (15) 7 (58) 3 (25)
Total (%) .................................................................................................... 79 (100) 31 (39) 8 (10)
*The association between biopsy category and the frequency of extraprostatic tumor growth at radical prostatectomy is statistically significant (Pearson chi-squared
test, two-tailed P  .01).
†Although an association between biopsy category and biochemical progression is also visible, it is not statistically significant (Pearson chi-squared test, two-tailed
P  .06).
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2). Of 1129 men with biopsy recommen-
dations, 102 (9%) did not undergo biopsy
because of refusal (49, or 48%) or medi-
cal reasons (53, or 52%). Of the 850 men
with a benign biopsy outcome during the
first round, 823 (97%) were invited for an
interim rescreen (27 men were not invited
back because they had reached the age of
76 years). Of these 823 men, 662 (80%)
accepted (Table 2). Of the 161 men who
did not visit, two (1%) had moved out of
the area and 16 (10%) had died of causes
other than prostate cancer. The reason for
the failure to visit was unknown for 143
men (89%). Of the 301 men recom-
mended for biopsy during the interim
round, 17 (6%) did not undergo biopsy
because of refusal (15, or 88%) or medi-
cal reasons (2, 12%).
After the various exclusions, 3616 men
were left at the beginning of the second
screening round. Of these, 593 (16%)
were not invited for the second round be-
cause they had reached the age of 76
years. Of the 3023 men who were ulti-
mately invited for the second screen, 2385
(79%) accepted (Table 2). Of the 638 men
who did not visit, 128 (20%) had moved
out of the area and 155 (24%) had died of
causes other than prostate cancer. In 12
men (2%), prostate cancer had been de-
tected outside the study screening. The
reason for not attending the second screen
was unknown for 343 men (54%). Of 481
biopsy recommendations, 41 men (9%)
did not undergo biopsy because of refusal
(31, or 76%) or medical reasons (10, or
24%).
Prostate Cancer Detection Rates
We compared the prostate cancer de-
tection rates during the first round screen
(prevalence screen), interim screens, and
second round of screening to determine
whether the rate of detecting prostate can-
cer would differ between subsequent
screening rounds. Table 2 shows that
prostate cancer detection rates were simi-
lar in all rounds. During the prevalence
screen, the detection rate was 4.3% (5.1%
if the interim round is included). The de-
tection rate of 3.9% in the second round
did not differ statistically significantly
from the rates in the first round (Pearson
chi-squared test, two-tailed P  .51 for
the first round versus the second round
and P  .36 for the total first round [in-
cluding the interim rounds] versus the
second round).
To correct for any possible bias caused
by age difference (ages in the first round
ranged from 55 to 75 years, while ages in
the second round ranged from 59 to 75
years), we examined the prostate cancer
detection rate specifically in those men
who were aged 59–75 years in the first
round (Table 2). We found that the detec-
tion rate was slightly higher in this group
of men during the first round. However,
this rate still did not differ statistically
significantly from that in the second
round (Pearson chi-squared test, two-
tailed P  .09).
Interval Cancers
The number of interval cancers (i.e.,
prostate cancers detected in a screened
population outside regular screening)
gives an indication of the efficacy of the
screening protocol. In the cohort studied,
prostate cancer was diagnosed outside the
regular screening rounds in only 12 men.
Prostate cancer in this group was mostly
clinically inapparent and was found coin-
cidentally at transurethral resection for
prostatism or cystoprostatectomy for
bladder cancer.
Age, Serum PSA Levels, and Tumor
Characteristics
To evaluate differences in cancer char-
acteristics (such as grade and size) be-
tween the subsequent rounds of screening
and their relationship with patient’s age
and serum PSA level, we compared these
parameters. In all rounds, the age of the
participants with prostate cancer did not
differ substantially from the age of the
participants who had undergone a biopsy.
Although biopsies were not performed
at serum PSA levels below 3 ng/mL in the
second round, the median serum PSA lev-
els of participants with prostate cancer
was lower in the second round than in the
first round (Table 3). In addition, PSA
levels at biopsy after the second round
screen did not predict the presence of ad-
enocarcinoma. That is, at the prevalence
(the first round) screen, serum PSA levels
at biopsy were statistically significantly
higher in participants with adenocarci-
noma (median PSA level  6.1 ng/mL)
than in participants with a benign biopsy
outcome (median PSA level  2.7 ng/
mL) (Mann–Whitney U test, two-tailed
P<.001). In the second round, however,
serum PSA levels at biopsy did not differ
between men with benign biopsy out-
comes (median, 4.5 ng/mL) and those
with adenocarcinoma (median, 4.3 ng/
mL) (Mann–Whitney U test, two-tailed
P  .57).
The amount of adenocarcinoma in sex-
tant biopsy sets was statistically signifi-
cantly lower in tumors detected at the sec-
ond round of screening than in tumors
detected at the first round (Mann–
Whitney U test, two-tailed P  .001;
Table 3). The median amount of cancer in
needle biopsy sets was 7.0 mm (95% con-
fidence interval [CI]  5.4 mm to 8.6
mm) in the first round and 4.1 mm (95%
CI  2.6 mm to 5.6 mm) in the second
round (P .001; Table 3). Nevertheless,
the average number of positive biopsy
cores in men with adenocarcinoma de-
creased only slightly, from 2.5 in the first
round to 2.2 in the second round (Pearson
Table 2. Prostate cancer detection rates at the different rounds of screening
No. invited
Screened, No.
(% of invited)
Biopsy recommendation,
No. (% of screened)
Performed biopsies,
No. (% of screened)
Prostate cancer
No.
% of
performed biopsies
% of
screened*
Round 1 4491 4133 (92.0) 1129 (27.3) 1027 (24.8) 177 17.2 4.3*
Round 1: men aged 59–75 y† — 3032 881 (29.1) 839 (27.7) 149 17.8 4.9*
Interim screens 823 662 (80.4) 301 (45.5) 284 (42.9) 33‡ 11.6 5.0
Total round 1 210 5.1*
Round 2 3023 2385 (78.9) 481 (20.2) 440 (18.4) 94 21.4 3.9*
*Statistical tests on prostate cancer detection rates (Pearson chi-squared test, two-tailed test): round 1 versus round 2, P  .51; total round 1 versus round 2,
P  .36); round 1 (ages 59–75 years) versus round 2, P  .09.
†To correct for age differences between the two rounds of screening, a separate calculation was done for men aged 59–75 years in round 1.
‡One additional case of prostate cancer was detected at a second interim screen that was performed in seven participants 1 year after the first interim screen.
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chi-squared test, P  .13; data not
shown).
In addition to the smaller amount of
cancer, prostate cancers detected at the
second round were better differentiated
than adenocarcinomas detected during the
combined first rounds (i.e., the prevalence
and interim screens). The median amount
of high-grade cancer (expressed in milli-
meters of cancer with Gleason growth
pattern 4 or 5) was statistically signifi-
cantly lower in adenocarcinomas detected
at the second round of screening than in
adenocarcinomas detected at the first
round (Mann–Whitney U test, two-tailed
P<.001; Table 3). Gleason score was sta-
tistically significantly lower in adenocar-
cinomas detected at the second round
(Pearson chi-squared test, two-tailed P
.001; Table 3). Thirty-six percent of the
adenocarcinomas detected in the first
round but only 16% of those detected in
the second round had a Gleason score of 7
or higher (mean difference  20% [95%
CI  10% to 30%]; P<.001).
To investigate whether the observed
differences in tumor characteristics were
reflected by serum PSA levels, we strati-
fied the frequency of biopsies, the fre-
quency of prostate cancer at biopsy, and
the median amount of tumor in biopsy
specimens to range of serum PSA levels
(Table 4). Both prostate cancer detection
frequencies and the amount of prostate
cancer in biopsy specimens at the preva-
lence screen were clearly associated with
serum PSA levels at screening (Table 4).
Despite overall higher serum PSA levels
at the interim screen, both detection fre-
quency and the amount of tumor in biopsy
specimens were lower than during the
prevalence screen, especially at high PSA
Table 3. Age, serum PSA levels, and tumor characteristics of participants at biopsy and participants with adenocarcinoma in the different rounds of screening
Round 1 prevalence screen Round 1 interim screen
Benign biopsies Cancer at biopsy Benign biopsies Cancer at biopsy
No. of participants 850 177 251 33
Mean age, y (standard deviation) 65.4 (5.8) 65.7 (5.6) 66.9 (5.1) 66.3 (6.0)
Serum PSA level, ng/mL, median (range) 2.7 (0.1–49.4) 6.1 (0.3–304.0) 5.1 (0.1–26.2) 5.4 (1.0–24.8)
Tumor length at biopsy, mm, median (range) 8.4 (0.8–72.5) 3.2 (0.7–10.6)
High-grade tumor length on biopsy, mm, mean
(standard deviation)/median (range)
4.4 (10.3)/0.0 (0.0–72.5),
available for 175 cases
0.7 (1.7)/0.0 (0.0–8.4),
available for 32 cases
Gleason score, No. (%)
4 6 (3) 1 (3)
5 12 (7) 2 (6)
6 91 (51) 22 (67)
7 42 (24) 7 (21)
8 22 (12) 1 (3)
9 3 (2) 0
10 1 (1) 0
Total round 1,
cancer at biopsy
Round 2 screen
Statistical tests on difference
between total round 1 and round 2Benign biopsies Cancer at biopsy
No. of participants 210 346 94
Mean age, y (standard deviation) 65.8 (5.7) 67.4 (4.5) 66.8 (4.6)
Serum PSA level, ng/mL, median (range) 5.8 (0.3–304.0) 4.5 (3.0–36.0) 4.3 (3.0–15.1)
Tumor length at biopsy, mm, median (range) 7.0 (0.7–72.5) 4.1 (1.1–56.1) Mann–Whitney U test, two-tailed
P  .001
High-grade tumor length on biopsy, mm,
mean (standard deviation)/median (range)
3.8 (9.6)/0.0 (0.0–72.5),
available for 208 cases
0.6 (1.7)/0.0 (0.0–10.6),
available for 93 cases
Mann–Whitney U test, two-tailed
P<.001
Gleason score, No. (%)
4 7 (3) 1 (1)
5 14 (7) 3 (3)
6 113 (54) 75 (80)
7 49 (23) 14 (15) Pearson chi-squared test, two-tailed
P  .001
8 23 (11) 1 (1)
9 3 (1) 0
10 1 (1) 0
Table 4. Cancer detection and tumor length at biopsy of participants in different PSA ranges during screening
Serum PSA
level range,
ng/mL
Round 1 prevalence screen Round 1 interim screen Round 2 screen
No. of
biopsies (%)
Cancer at
biopsy (%/%
of biopsies)
Cancer length
at biopsy, mm,
median (range)
No. of
biopsies (%)
Cancer at
biopsy (%/%
of biopsies)
Cancer length
at biopsy, mm,
median (range)
No. of
biopsies (%)
Cancer at
biopsy (%/%
of biopsies)
Cancer length
at biopsy mm,
median (range)
0–2.9 469 (46) 27 (15/6) 4.4 (1.1–31.8) 66 (23) 6 (18/9) 1.9 (1.0–6.0) 0 (0) 0 (0) —
3.0–3.9 42 (4) 10 (6/24) 5.4 (2.0–15.8) 13 (5) 3 (9/23) 4.4 (3.4–5.2) 157 (36) 35 (37/23) 3.3 (1.2–27.2)
4.0–9.9 437 (42) 95 (54/22) 9.2 (0.8–52.3) 178 (63) 20 (61/11) 3.0 (1.5–8.0) 252 (57) 52 (56/21) 5.2 (1.2–56.1)
10.0 79 (8) 45 (25/58) 14.6 (0.8–72.5) 27 (9) 4 (12/15) 2.6 (0.7–10.6) 31 (7) 7 (7/23) 4.2 (1.1–21.0)
Total 1027 (100) 177 (100/17.3) 8.4 (0.8–72.5) 284 (100) 33 (100/11.4) 3.2 (0.7–10.6) 440 (100) 94 (100/21.6) 4.1 (1.1–56.1)
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levels (10 ng/mL, Table 4). The same
trend was seen in the second round. That
is, cancer detection rates in the second-
round screen and the prevalence screen
were similar at serum PSA levels of 3
ng/mL to 10 ng/mL, but the frequency of
prostate cancer in biopsies performed at
serum PSA levels of 10 ng/mL or above
in the second-round screen was only half
of the frequency that was observed in the
prevalence screen.
In addition, the association between
the range of serum PSA levels and the
median length of tumor at biopsy that was
clearly present in the first round was lost
in the second round. Whereas in the first
round a serum PSA level of 10 ng/mL or
above was associated with a high amount
of cancer in biopsies, the amount of ad-
enocarcinoma present in biopsies per-
formed at serum PSA levels of 10 ng/mL
or above was comparatively low in the
second round (Table 4).
Categorization Model
To examine whether the 4-year inter-
val between PSA screenings in our study
resulted in an increase in advanced-stage
cancers at the second round, we compared
the biopsy-determined categories of
screen-detected prostate cancers in the
first and second rounds. We found a sub-
stantial difference in the distribution of
cancers in the three categories that we de-
fined. There was a moderate increase in
the number and the frequency of tumors
of both categories A and B, from 39
(19%) and 119 (56%), respectively, in the
first round to 28 (30%) and 60 (64%),
respectively, in the second round. The
number and the frequency of category C
tumors at biopsy, however, dropped dra-
matically, from 52 (25%) in the first
round to six (6%) in the second round
(mean difference  19% [95% CI 
11% to 26%]; P<.001). The category dis-
tribution of adenocarcinomas detected in
the second round was statistically signifi-
cantly lower than the distribution of ad-
enocarcinomas detected in the first round
(Pearson chi-squared test, two-tailed
P<.001). These results suggest that the
frequency of prostate cancer with adverse
prognostic features did decrease after the
interval of 4 years between the two
screening rounds in this study.
Baseline PSA Level in Men Who
Underwent a Biopsy in the Second
Round
Of the 440 participants who underwent
a biopsy in the second round, the baseline
serum PSA level (i.e., the PSA level
found during the first round of the study)
did not differ statistically significantly be-
tween men who turned out to have pros-
tate cancer and those who had a benign
biopsy outcome (Mann–Whitney U test,
two-tailed P .13). Baseline serum PSA
levels were even slightly lower in men
with prostate cancer detected in the sec-
ond round (median, 3.2 ng/mL; range,
0.7–9.3 ng/mL) than in men with a benign
biopsy outcome in the second round (me-
dian, 3.7 ng/mL; range, 0.5–35.7 ng/mL).
Thus, PSA values obtained during the
first round of the study (baseline PSA) did
not predict prostate cancer in subsequent
screening rounds.
DISCUSSION
Although annual PSA screening for
prostate cancer has been recommended by
the American Cancer Society since 1993
(2), to our knowledge, no study has yet
demonstrated that this is the optimum in-
terval for prostate cancer screening pro-
grams. Nevertheless, performing PSA
tests at an annual interval is now the most
commonly used method to screen for
prostate cancer in the United States. A
few reports (6–8), however, have postu-
lated that biannual screening would be
more cost-efficient because, although it is
not likely to miss curable prostate can-
cers, it does lead to substantial savings in
health-care costs. These reports are based
on models constructed by use of historical
data on prostate cancer incidence rates
and associated PSA levels; to our knowl-
edge, they have not yet been confirmed in
clinical practice.
Our study shows a substantial decrease
in both the amount and the grade of
screen-detected prostate cancers 4 years
after an initial prevalence screen (Tables
3 and 4). Relatively few advanced (cat-
egory C) tumors were found after the
4-year interval. In addition, the frequency
of prostate cancer in needle biopsies
dropped at high PSA ranges (Table 4).
These observations suggest that large
prostate cancers with high PSA values are
effectively detected during a prevalence
screen and that even an interval of 4 years
is not long enough for most large tumors
to develop.
The findings in our study are in strik-
ing contrast to those in breast cancer
screening: A pooled analysis of breast
cancer screening programs with a 1.5- to
3-year screening interval shows that, de-
spite a clear reduction in breast cancer-
related mortality associated with screen-
ing, the stage of the detected tumors does
not change statistically significantly dur-
ing subsequent rounds of screening (13).
It is important to note that the changes
in prostate cancer characteristics that we
observed in the current study took place
after a prevalence screen. In a previous
report (14), a comparison of characteris-
tics of prostate cancer detected at the
prevalence screen with those of a series of
non-screen-detected prostate cancers
showed a statistically significant drop in
stage and grade in the series detected dur-
ing the prevalence screen. The changes
between cancer detected at the first round
and cancer detected at the second round
of screening that were observed in the
current study suggest that periodic screens
at intervals of up to 4 years will have
an even greater beneficial effect on the
grade and stage at which prostate cancer
is detected.
Only very few reports have addressed
the question of whether different screen-
ing intervals would be applicable for men
with different clinical profiles (e.g., age,
comorbidity, or baseline serum PSA level
at the beginning of the screening pro-
gram). Carter et al. (6) used PSA conver-
sion rates to conclude that biannual
screening for prostate cancer can be
safely recommended in men with a base-
line serum PSA level below 2.0 ng/mL.
Annual testing would be required only for
men with PSA levels of 2.0 ng/mL or
above. This approach contends that base-
line PSA levels can be used to determine
the length of the interval by which screen-
ing should occur. Our findings do not
confirm this assumption because the base-
line PSA levels (observed at the preva-
lence screen) did not predict the occur-
rence of prostate cancer in the second
round.
Despite the substantial reduction in
both the amount and the grade of screen-
detected prostate cancer over the 4-year
interval between the first and second
rounds, our findings do not prove that
screening for prostate cancer has a ben-
eficial effect on prostate cancer mortality.
Moreover, screening for prostate cancer
potentially has the undesirable effect of
leading to overtreatment for clinically un-
important tumors. However, we saw little
indication of this in our study because the
fraction of category A tumors showed
only a moderate increase in the second
round. Category A tumors largely repre-
sent small well-differentiated adenocarci-
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nomas with an uncertain clinical signifi-
cance. Apart from potentially dangerous
carcinomas at an early stage, this category
is likely to harbor cancers that will not
pose a threat to their hosts during their
lifetime. Therefore, a substantial increase
in category A tumors would have been
more alarming than reassuring.
In screening for malignant diseases,
the interval between subsequent screens is
very important. When the interval be-
tween screens is too long, the chance in-
creases for the development of large in-
curable tumors between rounds of
screening. In the studied cohort of this
report, the number of interval cancers
was, however, limited. A total of 304 can-
cers were detected during the regular
screening rounds, and only 12 (3.8% of
all 316 cancers) were detected between
screening rounds.
Our study has several limitations. One
limitation, which applies to all studies that
rely on prostate sextant biopsy outcome
as an endpoint, is that tumor features ob-
served on sextant prostate needle biopsies
are not necessarily representative of ad-
enocarcinoma in the prostate gland. How-
ever, Table 1 shows that the frequency of
extraprostatic tumor growth is statistically
significantly higher for higher biopsy cat-
egories. The model that we used is also
associated with biochemical failure after
surgery (although this association is not
statistically significant). The observed
drop in category C tumors between the
two rounds, therefore, seems to indicate a
more favorable outcome for men in whom
cancer is detected at periodical rounds of
screening.
Another limitation is the decreased at-
tendance rate during the second round of
screening. Although an attendance rate of
79% after a 4-year interval could be con-
sidered reasonable, it might have led to a
bias in our results if men who forgo fur-
ther regular screens have clinical charac-
teristics that might favor the presence or
absence of prostate cancer.
Finally, our study may have been com-
promised by the use of different screening
protocols during the first and second
rounds of screening. In the second round,
biopsy recommendations no longer relied
on the outcome of DRE and TRUS, and
the threshold of serum PSA levels as a
sole tool for biopsy indication was low-
ered from 4 ng/mL to 3 ng/mL. Previous
investigations of the participants in ERSPC
(15,16) have shown that the number of
aggressive tumors detected at low PSA
levels is small. In addition, Table 4
clearly shows that differences in charac-
teristics between tumors detected in the
first round and tumors detected in the sec-
ond round were most pronounced in the
high PSA ranges (10 ng/mL), where the
protocols of both rounds were the same. It
is likely that the fraction of men with a
high PSA level caused by diseases other
than prostate cancer (e.g., chronic prosta-
titis or benign prostate hyperplasia) in-
creased during the second round of
screening, thereby accounting for the
lower detection rate at high serum PSA
levels and for the loss of the predictive
value of serum PSA levels for both the
presence and the amount of prostate can-
cer during the second round (Table 4).
Aside from these limitations, our re-
sults strongly suggest that, even over an
interval of 4 years between screening
rounds, there was no evidence of unfavor-
able changes in the characteristics of de-
tected carcinomas in the subsequent
rounds of prostate cancer screening. It ap-
pears that, during the prevalence screen,
large prostate cancers manifested by high
PSA levels are effectively detected. A
screening interval of 4 years seems short
enough to constrain the development of
most large tumors. Moreover, baseline
PSA levels found during a prevalence
screen do not predict the chance of pros-
tate cancer detection in subsequent
screening rounds.
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